Senetek PLC Investor Presentation at Rodman & Renshaw 9th Annual Healthcare Conference (November 2007)

Summary

Senetek PLC, a specialty life sciences company focused on aging and dermatological therapeutics, presented its business overview at the Rodman & Renshaw Healthcare Conference in November 2007. The presentation highlighted the company's scientific leadership, research collaborations, product pipeline, licensing agreements, and financial outlook. It included forward-looking statements about future revenues and product development, with a disclaimer about uncertainties and risks. The document is intended for informational purposes for investors and does not create any binding obligations between parties.

EX-10.1 2 dex101.htm SENETEK PLC PRESENTATION AT THE RODMAN AND RENSHAW CONFERENCE Senetek PLC Presentation at the Rodman and Renshaw Conference

Exhibit 10.1

Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

November 5 – 7, 2007 New York, New York

This presentation contains statements that may be considered ‘forward looking statements’ within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook and projections that might imply commercial potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward- looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

A Specialty Life Sciences Company Engaged in the Study of Senescence, the Science of Aging with an Initial Focus on Skincare and Dermatological Therapeutics

Headed by Professor Brian Clark, Ph.D., ScD., Senetek PLC’s Chief Scientist

? Achievements:

Discovery of the Initiation Codon for Protein Synthesis, 1965/1966

First Crystallization of tRNA, 1968

Determination of the First Structure of a GTP-Binding Protein, 1985

Structural Determination of the Ternary Complex, 1995

Past President of the International Union of Biochemistry and Molecular Biology, 1997

Head, European Chinese Biotechnology Transfer Task Force

? Publications:

Over 200 Papers

Books

World Renowned Scientific Advisory Board

? Sir John Walker, Ph.D., F.R.S., Scientific Advisor

Nobel Prize in Chemistry, 1997

Thought Leader in Nutrition & Aging

Expert on Mitochondria

? Professor Claudio Francheschi, M.D., EU Project Partner & Science Advisor

Professor, University of Bologna and Scientific Director of the Italian National Research Center on Aging-Department of Gerontological Studies, Bologna, Italy

Expert on Inflammation and the Genetics of Aging

? Dr. Gerald Weinstein, M.D.

University of California Department of Dermatology, Irvine (Emeritus)

World Renowned Expert on Photo Damaged Skin and Psoriasis

Institute of Experimental Botany—Czech Republic

Cooperative Research Agreement to Study Plant Physiology, Genetics and Biotechnology

Institute of Bioorganic Chemistry—Polish Academy of Sciences

Polish State Scientific Institution

PROTEOMAGE—European Integrated Project

Consortium of Leading European Researchers of Healthy Aging

National Hellenic Research Foundation of the Foundation of Biological Research and Biotechnology

University of California at Irvine—Department of Dermatology

Comprehensive Consulting, Pre-Clinical and Clinical Testing Services for Pharmaceutical and Cosmetic Compounds

Over 2000 Patented and Patent Applied for Compounds

Patent Applied for Suppression of Brain Tumors

Currently in Human Clinical Trials in Europe

Extraordinary Results for example individual diagnosed with grade 3 glioblastoma multiforme (average life expectancy from diagnosis equals 8 months) treated and alive 24 months post diagnosis